Macular disease management simplified

JENA/GERMANY, June 6, 2015

The ZEISS Retina Workplace helps eye care professionals get automated access to relevant clinical information at the point of decision. While redefining workflow efficiency in retina practices, the new ZEISS ophthalmology software makes it easier to manage macular diseases such as monitoring patients undergoing anti-VEGF therapy.

Eye care professionals who manage macular diseases can benefit from new ophthalmic software that supports them in making more confident decisions. The ZEISS Retina Workplace* solution – being presented at this year’s congress of the European Society of Ophthalmologists (SOE) in Vienna – utilizes data from the FORUM® eye care data management system from ZEISS. On display are combined data from the ZEISS CIRRUS-HD OCT, from ZEISS CIRRUS photo and from fundus imaging devices (independent from the manufacturer).  

The entire patient history at a glance

Until now, doctors had to manually locate the relevant reports to display. The Retina Workplace from ZEISS delivers the complete clinically relevant picture with fundus and OCT images at their fingertips in order to make a confident decision. Up to three data sets can be easily navigated simultaneously to directly compare multiple points in time – on a single intuitive screen, significantly reducing the time spent with data set interaction.

Along with providing an at-a-glance overview of the complete patient history of all macular OCT scans available in FORUM, the ZEISS Retina Workplace allows easy access to all images and analysis results. With the help of this fully interactive tracking solution, eye care professionals can efficiently monitor macular disorders – for example, the progression of age-related macular degeneration (AMD) of patients receiving anti-VEGF injections.

Transforming workflow efficiency and management of anti-VEGF patients

Anti-VEGF therapy has become the most important AMD treatment method. The drugs are injected on a regular basis, often monthly, to block a group of proteins in the body, called vascular endothelial growth factor (VEGF), that are known to play a significant role in the formation of the abnormal blood vessels that are responsible for the retina damage in wet macular degeneration.

Many physicians perform more than 1,000 injections annually, and treating up to 30 patients per day with anti-VEGF injections is not uncommon in many practices. Inefficiencies in this process easily can add up to several hours of extra work per week, especially in busy multi-doctor practices. The time pressure caused by a rising number of patients, as well as the changes in reimbursements in some countries, require the physicians to further improve their efficiency when monitoring AMD progression, especially while patients are being treated with anti-VEGF pharmaceuticals.

Doctors have to meet patients’ expectations on safe and effective treatments, and they also have to manage the rising numbers of patients in an efficient and reliable way. Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, says: “We are delighted to bring the benefits of this software solution now also to the field of age-related macular degeneration and other macular disorders.”

The ZEISS Retina Workplace and the FORUM Glaucoma Workplace deliver clinical value by building upon the capacities of the FORUM Data Management system. The ZEISS FORUM solution is designed specifically for eye care providers, focused on increasing data management efficiency in settings of all sizes: from individual ophthalmology and optometry practices to clinics and hospital departments to the government sector. FORUM supports eye care providers in their day-to-day work – improving workflow, simplifying decision making and helping drive better patient care and clinical outcomes.

* The ZEISS Retina Workplace is CE-Marked and 510(k) cleared by the US Food and Drug Administration, and it is approved for sale in many other countries, e.g. in Japan, India and Mexico.

Press contact:
Sebastian Frericks, Investor Relations, Carl Zeiss Meditec AG
Phone +49 (0)3641 220-331, Email: press .meditec @zeiss .com

For investors:
Sebastian Frericks, Investor Relations, Carl Zeiss Meditec AG
Phone +49 (0)3641 220-116, Email: investors .meditec @zeiss .com


Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The Company creates innovative visualization solutions in the field of microsurgery. Carl Zeiss Meditec AG's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiation therapy. With almost 3,000 employees, the Group generated revenue of € 909 million in financial year 2013/2014 (to 30 September).

The Group’s head office is in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading companies in the optical and optoelectronic industries.

For more information visit our website at: